From Wikipedia, the free encyclopedia
Chemical compound
Pyronaridine
Other names Pyronaridine tetraphosphate
Routes of administration Oral,
intramuscular injection ,
intravenous therapy
ATC code
Legal status
CLP (EU): Acute Tox. 3(H301), Eye Dam. 1 (H318), Repr. 2 (H361), Aquatic Chronic 4 (H413)[
clarification needed ]
4-[(7-Chloro-2-methoxy-pyrido[3,2-b]quinolin-10-yl)amino]-2,6-bis(pyrrolidin-1-ylmethyl)phenol
CAS Number
PubChem
CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (
EPA )
Formula C 29 H 32 Cl N 5 O 2
Molar mass 518.06 g·mol−1 3D model (
JSmol )
Clc1ccc6c(c1)nc2ccc(OC)nc2c6Nc5cc(CN3CCCC3)c(O)c(CN4CCCC4)c5
InChI=1S/C29H32ClN5O2/c1-37-26-9-8-24-28(33-26)27(23-7-6-21(30)16-25(23)32-24)31-22-14-19(17-34-10-2-3-11-34)29(36)20(15-22)18-35-12-4-5-13-35/h6-9,14-16,36H,2-5,10-13,17-18H2,1H3,(H,31,32)
Y Key:DJUFPMUQJKWIJB-UHFFFAOYSA-N
Y
N Y
(what is this?)
(verify)
Pyronaridine is an
antimalarial drug .
[1] It was first made in 1970 and has been in clinical use in China since the 1980s.
[2]
In a small (n=88) malaria study in Camaroon, pyronaridine had a 100% cure rate, compared with 60% for
chloroquine .
[3]
It is one of the components of the
artemisinin combination therapy
pyronaridine/artesunate (Pyramax).
[4]
It has also been studied as a potential anticancer drug,
[5] and treatment for Ebola. The combination of pyronaridine and artesunate has been evaluated to have a synergistic effect of stronger antiviral effect and less toxicity.
[6] The combination of pyronaridine and artesunate is being studied as a possible treatment for moderate to severe SARS-COV-2.
[7]
References
^ Croft SL, Duparc S, Arbe-Barnes SJ, Craft JC, Shin CS, Fleckenstein L, et al. (August 2012).
"Review of pyronaridine anti-malarial properties and product characteristics" . Malaria Journal . 11 : 270.
doi :
10.1186/1475-2875-11-270 .
PMC
3483207 .
PMID
22877082 .
^ Chang C, Lin-Hua T, Jantanavivat C (1992). "Studies on a new antimalarial compound: pyronaridine". Transactions of the Royal Society of Tropical Medicine and Hygiene . 86 (1): 7–10.
doi :
10.1016/0035-9203(92)90414-8 .
PMID
1566313 .
^ Ringwald P, Bickii J, Basco LK (April 1998).
"Efficacy of oral pyronaridine for the treatment of acute uncomplicated falciparum malaria in African children" . Clinical Infectious Diseases . 26 (4): 946–953.
doi :
10.1086/513942 .
PMID
9564481 .
^
"Pyramax" (PDF) . European Medicines Agency. 2016.
^ Villanueva PJ, Martinez A, Baca ST, DeJesus RE, Larragoity M, Contreras L, et al. (2018).
"Pyronaridine exerts potent cytotoxicity on human breast and hematological cancer cells through induction of apoptosis" . PLOS ONE . 13 (11): e0206467.
Bibcode :
2018PLoSO..1306467V .
doi :
10.1371/journal.pone.0206467 .
PMC
6218039 .
PMID
30395606 .
^ Lane TR, Massey C, Comer JE, Anantpadma M, Freundlich JS, Davey RA, et al. (November 2019).
"Repurposing the antimalarial pyronaridine tetraphosphate to protect against Ebola virus infection" . PLOS Neglected Tropical Diseases . 13 (11): e0007890.
doi :
10.1371/journal.pntd.0007890 .
PMC
6894882 .
PMID
31751347 .
^
Krishna S , Augustin Y, Wang J, Xu C, Staines HM, Platteeuw H, et al. (January 2021).
"Repurposing Antimalarials to Tackle the COVID-19 Pandemic" . Trends in Parasitology . 37 (1): 8–11.
doi :
10.1016/j.pt.2020.10.003 .
PMC
7572038 .
PMID
33153922 .